<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02078310</url>
  </required_header>
  <id_info>
    <org_study_id>ITI-007-200</org_study_id>
    <nct_id>NCT02078310</nct_id>
  </id_info>
  <brief_title>Study of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled, Multiple Oral Dose Escalation for Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric Volunteers and in Geriatric Patients With Dementia.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intra-Cellular Therapies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intra-Cellular Therapies, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 1b/2, Randomized, Double-blind, Placebo-Controlled, Multiple Oral Dose Escalation
      Study to Assess Safety, Tolerability and Pharmacokinetics of ITI-007 in Healthy Geriatric
      Volunteers and in Geriatric Patients with Dementia
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Actual">November 2014</completion_date>
  <primary_completion_date type="Actual">August 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>up to 7 days</time_frame>
    <description>Vital signs, 12-lead ECGs, clinical laboratory testing, and adverse events will be assessed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>pre-dose and multiple collection points up to 72 h after the last dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Exploratory measures of cognitive function</measure>
    <time_frame>Baseline and up to 7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory measures of agitation</measure>
    <time_frame>Baseline and up to 7 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Exploratory measures of subjective sleep</measure>
    <time_frame>Baseline and up to 7 days</time_frame>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Alzheimer's Disease</condition>
  <arm_group>
    <arm_group_label>ITI-007 Part 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 1: Healthy geriatric volunteers with multiple oral dose escalation up to and including 20 mg ITI-007</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 1</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 1: Healthy geriatric volunteers with placebo given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ITI-007 Part 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Part 2: Geriatric patients with dementia with ITI-007 given</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Part 2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Part 2: Geriatric patients with dementia with placebo given</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITI-007</intervention_name>
    <description>ITI-007 for Part 1</description>
    <arm_group_label>ITI-007 Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>ITI-007 for Part 1</description>
    <arm_group_label>Placebo Part 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ITI-007</intervention_name>
    <description>ITI-007 for Part 2</description>
    <arm_group_label>ITI-007 Part 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for Part 2</description>
    <arm_group_label>Placebo Part 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Part 1

          -  Healthy geriatric volunteers

          -  MMSE score of &gt;= 26 at screening

          -  BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening

        Part 2

          -  Geriatric patients with a clinical diagnosis of dementia

          -  MMSE score of &lt; 26 at screening

          -  BMI between 19.0 and 40.0 kg/m2 and a minimum body weight of 50 kg at screening

        Exclusion Criteria:

          -  Any clinically significant illness within 6 months before screening

          -  Any history of cancer within last 5 years

          -  History of Hepatitis B or C infection and elevated ALT, AST or bilirubin above the
             upper limit of normal level

          -  Any subject considered to be an imminent danger to themselves or others
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>65 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>March 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 5, 2014</study_first_posted>
  <disposition_first_submitted>November 8, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>November 8, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">November 14, 2017</disposition_first_posted>
  <last_update_submitted>November 13, 2017</last_update_submitted>
  <last_update_submitted_qc>November 13, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dementia,</keyword>
  <keyword>Healthy</keyword>
  <keyword>geriatric</keyword>
  <keyword>volunteers</keyword>
  <keyword>patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

